News Hub
The latest breaking stories
Access up-to-date news and information on a wide range of press releases including business, finance, technology, healthcare, entertainment, and more.
Discover the most important & comprehensive stories delivered directly to you daily.
- Property Real Estate
- 13/11/2026
- 09:28
Higher rates trigger rush to reassess home values as enquiries jump 20%
Key Facts: Opteon has recorded a 20 per cent year-on-year increase in direct valuation enquiries, with demand spiking around RBA decisions. Valuation enquiries increased…
- Contains:
- Building Construction
- 13/11/2026
- 09:23
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more NEW YORK--BUSINESS WIRE-- The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec.…
- Contains:
- Biotechnology, Medical Health Aged Care
- 13/11/2026
- 09:20
Aravax Announces Positive Results of Phase 2 Clinical Trial of PVX108, a Novel Immunotherapy for the Treatment of Peanut Allergy
Melbourne, Australia, 13 November 2026— Aravax, a clinical‑stage biotechnology company developing next‑generation therapies for food allergy, today announces positive topline results in children from its Phase 2 clinical trial involving its lead product, PVX108 for the treatment of peanut allergy. PVX108 is an investigational, next-generation immunotherapy which uses proprietary peptides designed to precisely retrain the immune system to tolerate peanut whilst minimising treatment-induced acute allergic reactions. It has been awarded FDA Fast Track designation for the treatment of peanut allergy. Dr Pascal Hickey, CEO, Aravax said, “PVX108 is the first therapy designed to precisely target the root cause of peanut…
- Agriculture Farming Rural
- 13/11/2026
- 09:07
Aris Mining Announces Positive PFS Results for the Toroparu Gold Project
5.9 Moz of Proven and Probable Gold Mineral Reserves at $1,950/oz Gold 5.6 Moz of Planned Gold Production Over 29 Years; 258 koz Annually…
- Contains:
- Books Literature, Entertainment
- 13/11/2026
- 09:01
Women’s Writers Awards Celebrate Australian Authors Libby Hathorn, Susanne Gervay, Jane Messer, Jude Chapman
Key Facts: Society of Women Writers Giving Woman a Voice announce Award Winners for Poetry, Fiction, Non-Fiction, Children Women’s Writers Awards Celebrate Australian Authors…
- Contains:
- Government Federal, Taxation
- 13/11/2026
- 08:15
Operation Resonance: ATO and FWO return to hospitality sector
This is a joint media release from the Australian Taxation Office (ATO) and Fair Work Ombudsman (FWO). The Australian Taxation Office (ATO) and Fair Work Ombudsman (FWO) returned to Melbourne’s hospitality sector this week as part of Operation Resonance, an operation featuring a series of surprise visits to businesses suspected of not paying employees correctly and operating outside the tax and super system. The 3-day operation in Melbourne’s CBD follows intelligence gathered from community tip-offs, data matching and previous compliance activities. ATO and FWO officers joined forces to visit more than 30 businesses, as part of broader efforts under the…
- Research Development
- 13/11/2026
- 07:37
Monash University welcomes the signing of Australian-EU Horizon Europe agreement in Brussels
Today in Brussels Australia’s Minister for Industry and Innovation, the Hon Tim Ayres, signed the agreement between Australia and the EU for access to its Horizon Europe initiative. This marks a moment when Australia’s research and development enters into a relationship with the world’s largest research and innovation funding programme, worth €95.5 billion. Monash University Vice-Chancellor and President, Professor Sharon Pickering, said the commencement of Australia’s association with Horizon Europe will be an important piece of elevating Australia’s research as a national asset. “Formal association with Horizon Europe represents a transformative opportunity for Australia’s higher education sector. It will enable…
- Medical Health Aged Care
- 13/11/2026
- 06:51
Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical Development Program into the United States
NOVATO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cyclarity Therapeutics, Inc., a clinical-stage biotechnology company developing cyclodextrin therapeutics to reverse atherosclerotic cardiovascular diseases and metabolic diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for UDP-003. UDP-003, designed by Cyclarity’s proprietary AI-enabled computational platform, is engineered to bind and extract oxidized cholesterol to restore cellular function and spur atherosclerotic plaque regression.The IND clearance authorizes the expansion of Cyclarity Therapeutics’ Phase 1b trials to the United States, complementing the ongoing study in Australia. The study (NCT06813339; CTx-001) is a…
- Medical Health Aged Care, Seniors Interest
- 13/11/2026
- 06:00
Monash scientists identify protein driving age-related organ damage
Monash University researchers have identified a protein that drives age-related damage in vital organs, opening a potential new avenue for treatments that could help people stay healthier as they get older. Published in Immunity, the research discovered a link between the protein Granzyme K and signs of ageing in the heart, liver and kidneys. Granzyme K is a protein produced by immune cells, with levels known to increase significantly with age in both mice and humans, but its precise role in age-related organ damage has remained unclear. Senior researcher Professor Nicole La Gruta, from the Monash Biomedicine Discovery Institute, said…
Media Outreach made fast, easy, simple.
Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.